Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual (S)-Ketamine PK Study in Healthy Participants
NCT04282746Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of esketamine in treatment-resistant depression (TRD), sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma Concentrations of (S)-ketamine at 24 hours and Plasma Concentrations of Nor-(S)-ketamine at 24 hours. Started Feb 2020; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT04282746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04282746.